Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan puts Trustpilot on 'positive catalyst watch' ahead of results

(Sharecast News) - Trustpilot rallied on Wednesday as JPMorgan Cazenove placed the shares on "positive catalyst watch" into results and said that underperformance year-to-date presents a buying opportunity. JPM noted that the shares are down 12% YTD, versus its wider European Software coverage up 7%, the Stoxx Europe 600 up 5% and the FTSE 250 down 4%.

"While the shares have enjoyed a strong run over the last two years (up circa 178% since March 2023), we struggle to justify this significant underperformance YTD (with shares down 23% in the last four weeks), given the above-average earnings growth and attractive free cash flow inflection," it said.

It also pointed out that Trustpilot has recently printed well above expectations growth in the US - a key growth market, which has been a strategic area of focus for management - which it expects to be a focus for the upcoming FY24 results, scheduled for 18 March.

"Through mid-2024, Trustpilot's shares temporarily underperformed, which we argued at the time was a buying opportunity, when shares were at 225p; amidst current market volatility, we see the current juncture of underperformance as a similarly attractive entry-point for a business that is growing at mid-teens while expanding margins at pace and returning capital to shareholders," JPM said.

"We leave our above-consensus estimates unchanged and with a lowered bar now heading into the results, we place the shares onto positive catalyst watch into the FY24 results, seeing outperformance being driven by earnings and free cash upside, positive US growth momentum, potential for further capital returns and share price mean reversion versus peers."

JPMorgan rates the shares at 'overweight' with a 350p price target.

At 0940 GMT, the shares were up 1.9% at 275p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.